FI4114465T3 - Anti-ifnar1-annosteluohjelma ihonalaista injektiota varten - Google Patents

Anti-ifnar1-annosteluohjelma ihonalaista injektiota varten Download PDF

Info

Publication number
FI4114465T3
FI4114465T3 FIEP22724683.2T FI22724683T FI4114465T3 FI 4114465 T3 FI4114465 T3 FI 4114465T3 FI 22724683 T FI22724683 T FI 22724683T FI 4114465 T3 FI4114465 T3 FI 4114465T3
Authority
FI
Finland
Prior art keywords
unit dose
disease
use according
ifnar1
inhibitor
Prior art date
Application number
FIEP22724683.2T
Other languages
English (en)
Finnish (fi)
Inventor
Catharina Lindholm
Yen Lin Chia
Rajendra Tummala
Lorin Roskos
Joachim Almquist
Tomas Rouse
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81750490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4114465(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of FI4114465T3 publication Critical patent/FI4114465T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Devices For Medical Bathing And Washing (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
FIEP22724683.2T 2021-04-23 2022-04-21 Anti-ifnar1-annosteluohjelma ihonalaista injektiota varten FI4114465T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US202163272851P 2021-10-28 2021-10-28
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Publications (1)

Publication Number Publication Date
FI4114465T3 true FI4114465T3 (fi) 2023-10-31

Family

ID=81750490

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22724683.2T FI4114465T3 (fi) 2021-04-23 2022-04-21 Anti-ifnar1-annosteluohjelma ihonalaista injektiota varten

Country Status (25)

Country Link
US (4) US20220340669A1 (enExample)
EP (2) EP4306541A3 (enExample)
JP (2) JP7484027B2 (enExample)
KR (2) KR20250092298A (enExample)
CN (2) CN120392997A (enExample)
AU (2) AU2022260531B2 (enExample)
BR (1) BR112023021761A2 (enExample)
CA (1) CA3216387A1 (enExample)
CL (1) CL2023003114A1 (enExample)
CO (1) CO2023015498A2 (enExample)
DK (1) DK4114465T5 (enExample)
ES (1) ES2963757T3 (enExample)
FI (1) FI4114465T3 (enExample)
HR (1) HRP20231255T1 (enExample)
HU (1) HUE063562T2 (enExample)
IL (1) IL307748A (enExample)
LT (1) LT4114465T (enExample)
MX (1) MX2023012465A (enExample)
PL (1) PL4114465T3 (enExample)
PT (1) PT4114465T (enExample)
RS (1) RS64821B1 (enExample)
SI (1) SI4114465T1 (enExample)
SM (1) SMT202300382T1 (enExample)
TW (1) TW202317182A (enExample)
WO (1) WO2022223714A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781705B1 (en) * 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
US20250002590A1 (en) * 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
DK1711207T3 (da) 2003-12-10 2013-03-11 Medarex Inc Interferon-alpha-antistoffer og anvendelse heraf
EP1781705B1 (en) * 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2008093166A2 (en) 2006-05-11 2008-08-07 Ghent University Sialoadhesin-related compositions and methods
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
ES2542836T3 (es) 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
CN101909444B (zh) 2007-11-05 2013-09-18 米迪缪尼有限公司 硬皮病治疗方法
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
ES2613055T3 (es) 2009-09-03 2017-05-22 Medimmune, Llc Diagnóstico de interferón de tipo 1
US9493570B2 (en) * 2012-06-13 2016-11-15 Medimmune, Llc Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
US11059897B2 (en) * 2018-09-18 2021-07-13 I-Mab Biopharma Us Limited Anti-IFNAR1 antibodies for treating autoimmune diseases
KR20210131354A (ko) * 2019-02-15 2021-11-02 아스트라제네카 아베 I형 인터페론-매개 장애
KR102766960B1 (ko) 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
AU2021279277A1 (en) 2020-05-29 2023-02-02 Astrazeneca Ab Treatment of cardiometabolic disease with inhibitors of type I interferon signalling
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
US20240327529A1 (en) 2020-11-18 2024-10-03 Astrazeneca Ab Steroid sparing
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
US20250002590A1 (en) 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Also Published As

Publication number Publication date
US20240360231A1 (en) 2024-10-31
CN120514844A (zh) 2025-08-22
CL2023003114A1 (es) 2024-04-19
US20220340669A1 (en) 2022-10-27
WO2022223714A1 (en) 2022-10-27
JP2024511227A (ja) 2024-03-12
US20230365698A1 (en) 2023-11-16
EP4306541A2 (en) 2024-01-17
MX2023012465A (es) 2024-04-04
CO2023015498A2 (es) 2023-11-30
SMT202300382T1 (it) 2024-01-10
BR112023021761A2 (pt) 2023-12-26
JP7484027B2 (ja) 2024-05-15
PT4114465T (pt) 2023-11-03
DK4114465T5 (da) 2024-07-22
HUE063562T2 (hu) 2024-01-28
AU2022260531B2 (en) 2024-03-07
AU2022260531A1 (en) 2023-11-30
PL4114465T3 (pl) 2024-04-08
AU2022260531A9 (en) 2023-12-07
KR20230166134A (ko) 2023-12-06
JP2024102205A (ja) 2024-07-30
AU2024201743A1 (en) 2024-04-04
CN120392997A (zh) 2025-08-01
IL307748A (en) 2023-12-01
EP4114465A1 (en) 2023-01-11
TW202317182A (zh) 2023-05-01
HRP20231255T1 (hr) 2024-02-02
RS64821B1 (sr) 2023-12-29
US12060429B2 (en) 2024-08-13
LT4114465T (lt) 2023-11-10
ES2963757T3 (es) 2024-04-01
CA3216387A1 (en) 2022-10-27
SI4114465T1 (sl) 2023-11-30
KR20250092298A (ko) 2025-06-23
EP4306541A3 (en) 2024-03-27
DK4114465T3 (da) 2023-10-30
EP4114465B1 (en) 2023-08-30
US20240400699A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
FI4114465T3 (fi) Anti-ifnar1-annosteluohjelma ihonalaista injektiota varten
Abram et al. Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat
Roh et al. Acupoint stimulation with diluted bee venom (apipuncture) alleviates thermal hyperalgesia in a rodent neuropathic pain model: involvement of spinal alpha2-adrenoceptors
Dodman et al. Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs
Jaffe et al. The rapid development of physical dependence on barbiturates
ES2224430T3 (es) Noribogaina en el tratamiento del dolor y de la toxicomania.
Pieretti et al. Long-term changes induced by developmental handling on pain threshold: effects of morphine and naloxone.
RU2016149316A (ru) Лечение ревматоидного артрита
Czuczwar et al. Effect of morphine and morphine-like analgesics on susceptibility to seizures in mice
Plotnikoff et al. Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics
RU2006143334A (ru) Способы лечения заболеваний с помощью статистических сополимеров
CN102348463B (zh) 白介素-22在预防和/或治疗多器官功能障碍综合症(mods)中的用途
Cragnolini et al. Anxiety-like behavior induced by IL-1β is modulated by α-MSH through central melanocortin-4 receptors
Evans et al. The effects of cholinergic blockade on the growth hormone and prolactin response to insulin hypoglycaemia
EP1450850B1 (en) Method of administering a thymosin alpha 1 peptide
Kitahata Spinal analgesia with morphine and clonidine
Xu et al. On the role of galanin in mediating spinal flexor reflex excitability in inflammation
Mallick et al. β-adrenergic modulation of male sexual behavior elicited from the medial preoptic area in rats
Lewis et al. Tolerance, physical dependence and opioid-seeking behavior: Dependence on diencephalic norepinephrine.
Sadeghi et al. Contribution of the intra-hippocampal orexin system in the regulation of restraint stress response to pain-related behaviors in the formalin test
Young et al. Differences in the development of tolerance to two anticonvulsant benzodiazepines in the amygdaloid kindled rat
Zuo et al. Brain lnterleukin-1 Is Involved in Generation of the Serum Suppressive Factor Induced by Restraint Stress in Mice.
RU2018114634A (ru) Режим введения комбинации антитела к cd20 и антитела к blys
Chung et al. Effect of imuthiol administration to normal or immunodeficient mice on IL1 and IL2 production and immune responses regulated by these mediators
Kraicer et al. ADRENAL CORTICAL RESPONSE TO INSULIN-INDUCED HYPOGLYCAEMIA IN THE RAT. II. Mediating Role of Adrenaline and/or Noradrenaline